Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Chan Yoon Cheah

Chan Yoon Cheah

Linear Clinical Research and Sir Charles Gairdner Hospital
Improving upon the standard of care for patients with Richter’s transformation 3:16
Improving upon the standard of care for patients with Richter’s transformation
Chan Yoon Cheah • 23 Nov 2023
Advancing MCL treatment: combination therapies and updates from SYMPATICO 2:38
Advancing MCL treatment: combination therapies and updates from SYMPATICO
Chan Yoon Cheah • 23 Nov 2023
BCL2 and BTK dual-inhibition with sonrotoclax + zanubrutinib in previously untreated CLL and SLL 4:05
BCL2 and BTK dual-inhibition with sonrotoclax + zanubrutinib in previously untreated CLL and SLL
Chan Yoon Cheah • 23 Nov 2023
The role of epcoritamab in third-line or later LBCL 3:09
The role of epcoritamab in third-line or later LBCL
Chan Yoon Cheah • 16 Jun 2023
Promising agents emerging for Richter’s transformation 1:15
Promising agents emerging for Richter’s transformation
Chan Yoon Cheah • 16 Jun 2023
BRUIN study: updated two-year subgroup analysis of pirtobrutinib for BTKi pre-treated MCL 3:06
BRUIN study: updated two-year subgroup analysis of pirtobrutinib for BTKi pre-treated MCL
Chan Yoon Cheah • 16 Jun 2023
Pirtobrutinib shows efficacy in BTKi refractory Waldenström’s macroglobulinemia patients 2:51
Pirtobrutinib shows efficacy in BTKi refractory Waldenström’s macroglobulinemia patients
Chan Yoon Cheah • 9 Dec 2022
Results from the first-in-human trial of TG-1801 in patients with B-cell lymphoma 3:48
Results from the first-in-human trial of TG-1801 in patients with B-cell lymphoma
Chan Yoon Cheah • 9 Dec 2022
The role of the cardio-oncologist in the treatment of patients with hematological malignancies 2:07
The role of the cardio-oncologist in the treatment of patients with hematological malignancies
Chan Yoon Cheah • 9 Dec 2022
The benefits of bispecific antibodies over CAR-T cell therapy in lymphoma 6:23
The benefits of bispecific antibodies over CAR-T cell therapy in lymphoma
Chan Yoon Cheah • 9 Dec 2022
TG-1701, a novel BTKi, in B-cell malignancies 2:21
TG-1701, a novel BTKi, in B-cell malignancies
Chan Yoon Cheah • 22 Nov 2021
Efficacy and safety of BGB-11417 in B-cell malignancies 3:30
Efficacy and safety of BGB-11417 in B-cell malignancies
Chan Yoon Cheah • 22 Nov 2021
DLBCL updates at ASH 2021 2:59
DLBCL updates at ASH 2021
Chan Yoon Cheah • 22 Nov 2021
BGB-11417-101: first-in-human trial of BGB-1147 for R/R B-cell malignancies 3:04
BGB-11417-101: first-in-human trial of BGB-1147 for R/R B-cell malignancies
Chan Yoon Cheah • 26 May 2021
TG-1701: monotherapy & combination with U2 for CLL and lymphoma 3:33
TG-1701: monotherapy & combination with U2 for CLL and lymphoma
Chan Yoon Cheah • 26 May 2021
R-CHOP dose intensity and survival outcomes in DLBCL 1:57
R-CHOP dose intensity and survival outcomes in DLBCL
Chan Yoon Cheah • 26 May 2021
The content of VJHemOnc is intended for healthcare professionals